期刊
THERANOSTICS
卷 11, 期 5, 页码 2218-2231出版社
IVYSPRING INT PUBL
DOI: 10.7150/thno.53056
关键词
Cancer; phototherapy; immunotherapy; photo-immunotherapy; combination therapy
资金
- US National Institutes of Health [CA205348]
- Guangdong Province Key Area RD Program [2019B110233004]
- Hainan University R&D Program (KYQD) [20074]
The combination of targeted therapy and immunotherapy is considered an ideal strategy for treating metastatic cancer, with phototherapy emerging as a promising targeted therapy that can initiate antitumor immune responses through induced immunogenic tumor cell death. The use of phototherapy in conjunction with immunoadjuvant therapy has shown to induce a systemic antitumor immune response, controlling residual tumor cells at the treatment site and distant metastases.
Targeted therapy and immunotherapy in combination is considered the ideal strategy for treating metastatic cancer, as it can eliminate the primary tumors and induce host immunity to control distant metastases. Phototherapy, a promising targeted therapy, eradicates primary tumors using an appropriate dosage of focal light irradiation, while initiating antitumor immune responses through induced immunogenic tumor cell death. Recently, phototherapy has been employed to improve the efficacy of immunotherapies such as chimeric antigen receptor T-cell therapy and immune checkpoint inhibitors. Phototherapy and immunoadjuvant therapy have been used in combination clinically, wherein the induced immunogenic cell death and enhanced antigen presentation synergy, inducing a systemic antitumor immune response to control residual tumor cells at the treatment site and distant metastases. This review summarizes studies on photo-immunotherapy, the combination of phototherapy and immunotherapy, especially focusing on the development and progress of this unique combination from a benchtop project to a promising clinical therapy for metastatic cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据